AC Immune (NASDAQ:ACIU - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $1.98 million for the quarter.
AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. AC Immune had a negative return on equity of 44.60% and a negative net margin of 177.79%. The firm had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.99 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AC Immune Stock Performance
ACIU stock traded down $0.04 on Friday, hitting $2.12. 88,622 shares of the company's stock were exchanged, compared to its average volume of 147,044. The firm has a 50 day moving average price of $2.02 and a two-hundred day moving average price of $2.08. The stock has a market cap of $212.87 million, a P/E ratio of -3.66 and a beta of 1.65. AC Immune has a 12-month low of $1.43 and a 12-month high of $3.98.
Wall Street Analyst Weigh In
Several research firms have weighed in on ACIU. HC Wainwright dropped their price target on AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Wall Street Zen upgraded AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th.
Read Our Latest Analysis on AC Immune
Institutional Trading of AC Immune
An institutional investor recently raised its position in AC Immune stock. Acadian Asset Management LLC grew its stake in AC Immune (NASDAQ:ACIU - Free Report) by 87.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 371,177 shares of the company's stock after buying an additional 172,796 shares during the quarter. Acadian Asset Management LLC owned 0.37% of AC Immune worth $679,000 as of its most recent SEC filing. Institutional investors own 51.36% of the company's stock.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Stories
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access